Navigation Links
AdvanDx Receives FDA 510(k) Clearance for E. coli/P. aeruginosa PNA FISH(R)
Date:1/30/2009

First Diagnostic Test for Identifying E. coli and P. aeruginosa Directly from Positive Blood Cultures

PNA FISH to Provide Critical Results 24-48 Hours Sooner Than Conventional Methods Helping Clinicians to Improve Care and Outcomes for 100,000 Patients with Bloodstream Infections

WOBURN, Mass. and VEDBAEK, Denmark, Jan. 30 /PRNewswire/ -- AdvanDx today announced it received FDA 510(k) clearance for E. coli/P. aeruginosa PNA FISH(R) to identify Escherichia coli and/or Pseudomonas aeruginosa directly from positive blood cultures. E. coli/P. aeruginosa PNA FISH is the first-ever test for identifying E. coli and P. aeruginosa directly from positive blood cultures and the latest addition to AdvanDx's easy-to-use, molecular-based PNA FISH diagnostics platform. PNA FISH tests now provide rapid species identification for the vast majority of Gram-stain results in hours instead of days, enabling therapy guiding results for 95-99% of patients with positive blood cultures.

Every year, an estimated 100,000 patients develop bloodstream infections (BSI) due to Gram-negative pathogens such as E. coli and/or P. aeruginosa. Patients afflicted by these serious infections spend an average of 5-24 days in the hospital, suffer mortality rates as high as 40% and cost institutions on average $40,000 to $60,000 per case (1,2). These grim statistics are due in part to Gram-negative bacteria's increasing resistance to a multitude of antibiotic agents, especially in P. aeruginosa, creating complex therapy decisions for clinicians. Treatment challenges are further compounded by conventional laboratory testing methods for Gram-negative pathogens that take 24-48 hours to provide results, forcing clinicians to treat patients empirically which may not provide full coverage for the infecting pathogen.

Studies show that providing a 24 hour "head start" on appropriate narrow-spectrum therapy for Gram-negative bloodstream infections may improve clinical outcomes, reduce antibiotic resistance rates and reduce the incidences of adverse events (3,4). E. coli/P. aeruginosa PNA FISH will, for the first time, enable microbiology labs to provide clinicians rapid, accurate Gram-negative pathogen identification in hours, not days.

"We are very excited to launch E. coli/P. aeruginosa PNA FISH as another critical tool to help laboratories and clinicians provide faster results and improve care for patients with life threatening infections," said Thais T. Johansen, President and CEO of AdvanDx. "Our PNA FISH diagnostic platform now provides a complete solution by enabling rapid identification results for 95 to 99% of all patients with positive blood cultures," Johansen concluded.

About AdvanDx

AdvanDx is the world's leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx's easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.

AdvanDx's products employ standard laboratory techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products as integral parts of their medical care.

For more information visit www.AdvanDx.com

References:

  1. Kang et al. Antimicrob Agents Chemother. 2005 Feb;49(2):760-6.
  2. Paterson et al. Clin Infect Dis. 2008 Sep 15;47 Suppl 1:S14-20.
  3. Slama et al. Crit Care. 2008;12 Suppl 4:S4.
  4. Thom et al. BMC Infect Dis. 2008 Sep 15;8:116.

PN1514A


'/>"/>
SOURCE AdvanDx
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
2. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
3. AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM)
4. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... light to control cells — optogenetics — is key to exciting advances in ... the art, spatially patterned light projected via free-space optics stimulates small, transparent organisms ...
(Date:12/8/2016)... BARCELONA, Spain , Dec. 8, 2016  Anaconda ... on the development of the next generation neuro-thrombectomy system ... the appointment of Tudor G. Jovin, MD to join ... to serve as a strategic network of scientific and ... progresses the development of the ANCD BRAIN ® ...
(Date:12/8/2016)... ... December 08, 2016 , ... This CAST literature review ... biotech crops. The authors focus on the economic effects in countries that are major ... new biotech crops and the resultant risk of low level presence (LLP) puts large ...
(Date:12/8/2016)... HOWELL, N.J. , Dec. 8, 2016 /PRNewswire/ ... aquatic augmentation remediation technologies and selected NewTechBio,s NT-MAX ... , a microbial based beneficial bacteria, in conjunction ... Inc., to correct deficiencies with National Pollutant Discharge ... basin 281-8H has experienced a steady history of ...
Breaking Biology Technology:
(Date:12/7/2016)... Israel , December 7, 2016 BioCatch ... the expansion of its patent portfolio, which grew to over 40 granted ... , , ... its recently filed patent entitled " System, Device, and Method ... technology that enables device makers to forego costly hardware components needed to ...
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
Breaking Biology News(10 mins):